Indeed, patients with relapsed or refractory cHL typically experience some of the highest response rates reported for PD-1/PD-L1 inhibitors, with even single-dose nivolumab showing exceptional activity (23, 24). Here, PDCD1 is linked to classic Hodgkin lymphoma.